Corifollitropin alfa, Hybrid follicle-stimulating hormone (FSH)

Specification

• Cat#: THP-0141
• Product Name: Corifollitropin alfa, Hybrid follicle-stimulating hormone (FSH)
• Description: It is recombinantly made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa.
• Sequences: Not Available
• Species: Human
• Molecular Weight: 25398.0389 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 195962-23-3
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 150ug

Pharmaceutical Information

• Pharmaceutical Application: Corifollitropin alfa
• Applications: Controlled ovarian stimulation in cases of women who are undergoing fertility treatment to stimulate the development of more than one mature egg simultaneously in the ovaries in combination with a gonadotrophin-releasing hormone (GnRH) antagonist (a type of medicine also used in fertility treatments).
• Examples of Clinical Use: women infertility
• Pharmacodynamics: A single dose of the product could initiate and sustain multi-follicular growth in patients undergoing controlled ovarian stimulation, such as during in vitro fertilization or intracytoplasmic sperm injection.This drug is structurally similar to follicle stimulating hormone (FSH), a hormone naturally present in females. FSH stimulates the production of eggs (ova) in the ovaries. In the product, a peptide is attached to the FSH to prolong its activity. As a result, one single dose of the medicine can be administered to stimulate egg production for seven days, replacing daily injections that are normally needed with other FSH medicines.In phase III clinical trials, the number of oocytes retrieved following the administration of corifollitropin alfa was slightly higher compared with the number observed with daily recombinant FSH treatment.
• Mechanism of action: Corifollitropin alfa is a long-lasting single injection fusion protein which lacks luteinizing hormone (LH) activity. Only one injection is needed for the first 7 days, which replaces the first 7 daily injections of traditional follicle stimulating hormone (FSH). It is a follicle-stimulation hormone (human α-subunit reduced), a combination of follicle stimulation hormone (human β-subunit reduced) fusion protein with 118-145-chorionic gonadotropin (human β-subunit). Frequent, repetitive injections increase stress and error rates, and are often a burden for women, leading to therapy noncompliance.
• Affected organisms: Humans and other mammals
• Targets: Target 1. Follicle-stimulating hormone receptor